MST2 silencing induces apoptosis and inhibits tumor growth for estrogen receptor alpha-positive MCF-7 breast cancer
Related Experiment Video
Updated: Dec 7, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Joonwoo Park1, Ga Hee Kim2, Jeonggeun Lee1
1Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Kwangjin-gu, Seoul 05006, South Korea.
Abstract:
Mammalian sterile 20-like kinase 1/2 (MST1/2) plays an important role in cell growth and apoptosis and functions as a tumor suppressor. Previously, we showed that MST2 overexpression activates Estrogen receptor alpha (ERα) in human breast cancer MCF-7 cells in the absence of a ligand. Here, we examined the role of MST2 in the growth of ER-positive MCF-7 cells. Cell cycle, apoptosis, and mammosphere formation assay method were implemented to detect the biological effects of MST2 ablation on the growth of MCF-7 cells in vitro. The effect of MST2-siRNA on MCF-7 cells tumor growth in vivo was studied in tumor-bearing mouse model. Kaplan-Meier plotter analysis was used to determine the effect of MST2 on overall survival in breast cancer patients. MST2 overexpression increased cell viability marginally. The ablation of MST2 using siRNA dramatically suppressed the viability of the MCF-7 cells, but not ER-negative MDA-MB-231 breast cancer cells. Furthermore, MST2 knockdown increased caspase-dependent apoptosis and led to decreased mammosphere formation. Treatment of MCF-7 tumor-bearing mice with MST2 siRNA significantly inhibited tumor growth. The tumor weight was reduced further when tamoxifen was added. Patients with ER-positive breast cancer with low MST2 expression had better overall survival than did those with high MST2 expression in Kaplan-Meier survival analyses using public datasets. Our results provide new insight into the role of MST2, a key component of the Hippo signaling pathway, in mediating breast cancer progression.
Insights
Mammalian sterile 20-like kinase 2 (MST2) suppresses estrogen receptor-positive breast cancer growth by promoting apoptosis and inhibiting cell viability. Low MST2 expression correlates with better survival in these patients.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Mammalian sterile 20-like kinase 1/2 (MST1/2) are key regulators of cell growth and apoptosis, acting as tumor suppressors.
- Previous studies indicated MST2 overexpression activates Estrogen Receptor alpha (ERα) in ER-positive breast cancer cells.
- The precise role of MST2 in ER-positive breast cancer progression requires further elucidation.
Purpose of the Study:
- To investigate the role of MST2 in the proliferation and progression of ER-positive human breast cancer MCF-7 cells.
- To evaluate the therapeutic potential of targeting MST2 in ER-positive breast cancer.
Main Methods:
- In vitro assays including cell cycle, apoptosis, and mammosphere formation were used to assess MST2 ablation effects.
- In vivo studies utilized a tumor-bearing mouse model treated with MST2-siRNA.
- Kaplan-Meier plotter analysis of public datasets examined MST2's impact on overall survival in breast cancer patients.
Main Results:
- MST2 ablation significantly suppressed MCF-7 cell viability, induced caspase-dependent apoptosis, and reduced mammosphere formation.
- MST2 knockdown did not affect ER-negative MDA-MB-231 cells, highlighting ER-dependency.
- In vivo, MST2-siRNA treatment inhibited tumor growth, with further reduction observed when combined with tamoxifen.
Conclusions:
- MST2 plays a critical role in promoting ER-positive breast cancer cell growth and progression.
- Targeting MST2, a component of the Hippo signaling pathway, represents a potential therapeutic strategy for ER-positive breast cancer.
- Low MST2 expression is associated with improved overall survival in ER-positive breast cancer patients.
More Related Videos
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...

